Efficacy of Enhanced Cytokine-Induced Killer Cells as an Adjuvant Immunotherapy for Renal Cell Carcinoma: Preclinical and Clinical Studies

Figure 6

Prognosis of patients in the enhanced CIK treatment group and control group. (a) Progression-free survival (PFS) and (b) overall survival (OS) were calculated by Kaplan–Meier analysis. Differences between the treatment group and control group were compared using the logRank test. (c) The representative CT scan images of lung metastases in RCC patients after CIK cells treatment. Case 1: a patient of RCC with lung metastasis at the beginning of follow-up, whose lung metastasis developed slowly during the 60 months follow-up period and no more metastatic lesion was observed. Case 2: a patient of RCC with lung metastasis at the beginning of follow-up, and the lung metastasis did not develop obviously in 18 months.

(a)

(b)

(c)